These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1153 related articles for article (PubMed ID: 538574)

  • 1. Increased immunogenicity of B16 melanoma clones selected for their ability to metastasize from a heterogeneous primary tumor.
    Steele GD; Richie JP; Wang BS; Mannick JA; Wilson RE
    Surg Forum; 1979; 30():132-3. PubMed ID: 538574
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cytotoxic immunity indices of melanoma B16 growth in mice].
    Korosteleva TA; Veresova OV
    Vopr Onkol; 1980; 26(1):67-70. PubMed ID: 7355591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
    Celik C; Lewis DA; Goldrosen MH
    Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases.
    Poste G; Doll J; Brown AE; Tzeng J; Zeidman I
    Cancer Res; 1982 Jul; 42(7):2770-8. PubMed ID: 7083167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenogeneic DNA immunization in melanoma models for minimal residual disease.
    Hawkins WG; Gold JS; Blachere NE; Bowne WB; Hoos A; Lewis JJ; Houghton AN
    J Surg Res; 2002 Feb; 102(2):137-43. PubMed ID: 11796010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW; Demsey A
    Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic differences among B16 melanoma variants selected for their differing abilities to metastasize: a possible mechanism for effective adjuvant immunotherapy.
    Steele G; Wang BS; Ghavamzadah G; Fallon M; Richie J; Wilson RE; Mannick JA
    J Surg Oncol; 1980; 15(1):71-83. PubMed ID: 6158632
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effects and parallel in vitro cytotoxicity of splenocytes harvested from treated or control C57BL/6J mice after adjuvant immunotherapy of pulmonary metastases using xenogeneic RNA specific to B16 murine melanoma.
    Wang BS; Steele G; Mannick JA; Fallon M; Onikul SR
    Cancer Res; 1979 May; 39(5):1702-7. PubMed ID: 427807
    [No Abstract]   [Full Text] [Related]  

  • 10. Biological behavior of malignant melanoma cells correlated to their survival in vivo.
    Fidler IJ
    Cancer Res; 1975 Jan; 35(1):218-24. PubMed ID: 1109790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
    LeGrue SJ; Hearn DR
    Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
    Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
    Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors.
    Baniyash M; Smorodinsky NI; Yaakubovicz M; Witz IP
    J Immunol; 1982 Sep; 129(3):1318-23. PubMed ID: 7108209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of antigenicity of melanoma cells grown in 5-bromodeoxyuridine to reduced tumorigenicity.
    Silagi S; Newcomb EW; Weksler ME
    Cancer Res; 1974 Jan; 34(1):100-4. PubMed ID: 4358536
    [No Abstract]   [Full Text] [Related]  

  • 15. Differences in cell density associated with differences in lung-colonizing ability of B16 melanoma cells.
    Baniyash M; Netanel T; Witz IP
    Cancer Res; 1981 Feb; 41(2):433-7. PubMed ID: 7448787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity in growth inhibition by beta-trans-retinoic acid of metastatic B16 melanoma clones and in vivo-selected cell variant lines.
    Lotan R; Nicolson GL
    Cancer Res; 1979 Dec; 39(12):4767-71. PubMed ID: 498105
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of host immunity to phenotypically diverse B16 melanoma clones. Implications for tumor growth and metastasis.
    Stackpole CW; Alterman AL; Braverman S; Rappaport I
    Invasion Metastasis; 1987; 7(6):346-66. PubMed ID: 3436737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity.
    Fidler IJ; Gersten DM; Budmen MB
    Cancer Res; 1976 Sep; 36(9 pt.1):3160-5. PubMed ID: 975082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of polymorphonuclear leukocytes in the pulmonary clearance of arrested cancer cells.
    Glaves D
    Invasion Metastasis; 1983; 3(3):160-73. PubMed ID: 6329986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.